MCID: GLC003
MIFTS: 53

Glucose Intolerance

Categories: Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 11 28 53 5 43 14 75
Impaired Glucose Tolerance 71
Malabsorption of Glucose 11
Glucose: Malabsorption 11
Glucose: Intolerance 11

Classifications:



External Ids:

Disease Ontology 11 DOID:10603
MeSH 43 D018149
NCIt 49 C34646
SNOMED-CT 68 267426009
UMLS 71 C0271650

Summaries for Glucose Intolerance

MalaCards based summary: Glucose Intolerance, also known as impaired glucose tolerance, is related to lipodystrophy, familial partial, type 2 and abdominal obesity-metabolic syndrome 1. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA-Leu (UUA/G) 1), and among its related pathways/superpathways are Signal Transduction and PI3K-Akt signaling pathway. The drugs Curcumin and Orlistat have been mentioned in the context of this disorder. Affiliated tissues include pancreatic islet, skeletal muscle and ovary, and related phenotypes are homeostasis/metabolism and adipose tissue

Wikipedia: 75 Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels... more...

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 458)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 32.5 LEP INS ADIPOQ
2 abdominal obesity-metabolic syndrome 1 31.9 SLC2A4 RETN LPL LEPR LEP INS
3 prediabetes syndrome 31.5 SLC2A4 SHBG RETN LPL LEPR LEP
4 non-alcoholic fatty liver disease 31.3 RETN LPL LEPR LEP INSR INS
5 gestational diabetes 31.3 SLC2A4 SHBG RETN LEPR LEP INSR
6 type 1 diabetes mellitus 31.3 LPL LEPR LEP INS IGF1 GHRL
7 coronary heart disease 1 31.2 LPL INS ADIPOQ
8 hypercholesterolemia, familial, 1 31.2 LPL INS GPT
9 polycystic ovary syndrome 31.2 SLC2A4 SHBG RETN LEP INSR INS
10 liver disease 31.1 RETN LEPR LEP INSR INS GPT
11 hyperinsulinism 31.1 SLC2A4 SHBG RETN LPL LEPR LEP
12 non-alcoholic steatohepatitis 31.1 LEP INS GPT GCG ADIPOQ
13 pre-eclampsia 31.1 SHBG LEPR LEP INS IGF1 GPT
14 nutritional deficiency disease 31.1 RETN LEPR LEP IGF1 GHRL ADIPOQ
15 uremia 31.0 RETN LPL LEP INS ENPP1
16 atherosclerosis susceptibility 31.0 RETN LPL LEP INS ADIPOQ
17 familial hyperlipidemia 31.0 LPL LEP INS GCK ADIPOQ
18 acromegaly 31.0 SHBG LEP INS IGF1 GHRL ADIPOQ
19 adult syndrome 31.0 SLC2A4 LEP INS IGF1 ADIPOQ
20 hyperglycemia 31.0 RETN PCK2 LPL LEP INSR INS
21 leptin deficiency or dysfunction 31.0 SLC2A4 RETN LPL LEPR LEP INS
22 chronic kidney disease 31.0 LPL LEP INS IGF1 GHRL ENPP1
23 kidney disease 30.9 RETN LEP INSR INS IGF1 GHRL
24 fatty liver disease 30.9 RETN LPL LEPR LEP INSR INS
25 body mass index quantitative trait locus 11 30.9 SLC2A4 SHBG RETN LPL LEPR LEP
26 liver cirrhosis 30.9 SLC2A4 RETN LEPR LEP INSR INS
27 hyperandrogenism 30.8 SHBG RETN INSR INS IGF1 ADIPOQ
28 hyperthyroidism 30.8 SHBG RETN LEP INS IGF1 GPT
29 cardiovascular system disease 30.8 SHBG RETN LPL LEPR LEP INS
30 insulin-like growth factor i 30.8 SHBG LEP INSR INS IGF1 GHRL
31 type 2 diabetes mellitus 30.8 SLC2A4 SHBG RETN PCK2 LPL LEPR
32 vascular disease 30.8 RETN LPL LEP INS IGF1 ADIPOQ
33 fetal macrosomia 30.7 LEP INSR INS IGF1
34 lipid metabolism disorder 30.7 SLC2A4 SHBG RETN LPL LEPR LEP
35 apnea, obstructive sleep 30.7 RETN LEP INS IGF1 GPT GHRL
36 conn's syndrome 30.7 RETN LEP INS IGF1 GHRL GCG
37 hypothyroidism 30.7 SHBG RETN LPL LEP INS IGF1
38 hypoglycemia 30.7 SLC2A4 PCK2 LEP INSR INS IGF1
39 lipoprotein quantitative trait locus 30.7 RETN LPL INS GPT GCG ADIPOQ
40 pituitary gland disease 30.7 INS IGF1 GCG
41 sleep apnea 30.7 RETN LEPR LEP INS IGF1 GPT
42 arteriosclerosis 30.6 SHBG INS GPT GHRL ADIPOQ
43 heart disease 30.6 RETN LPL INS IGF1 GPT GCG
44 pheochromocytoma 30.6 LEP INSR IGF1 ADRB3 ADIPOQ
45 acanthosis nigricans 30.6 SLC2A4 SHBG LEP INSR INS IGF1
46 acute pancreatitis 30.6 RETN LPL INS GPT
47 anovulation 30.5 SHBG LEP INS IGF1 GHRL
48 peripheral nervous system disease 30.5 LEP INS IGF1 GPT GCG DPP4
49 deficiency anemia 30.5 LEP INS IGF1 GPT GHRL
50 beta-thalassemia 30.5 LEP INS IGF1 GPT

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ADIPOQ ADRB3 DPP4 ENPP1 GCG GCK
2 adipose tissue MP:0005375 10.27 ADIPOQ ADRB3 ENPP1 GHRL IDE IGF1
3 growth/size/body region MP:0005378 10.25 ADIPOQ ADRB3 DPP4 ENPP1 GCG GCK
4 muscle MP:0005369 10.19 ADIPOQ ENPP1 IGF1 INS INSR LEP
5 liver/biliary system MP:0005370 10.18 ADIPOQ ENPP1 GCK INS INSR LEP
6 endocrine/exocrine gland MP:0005379 10.18 ADIPOQ ADRB3 DPP4 GCG GCK GHRL
7 renal/urinary system MP:0005367 10.16 ADIPOQ ENPP1 GCG GCK IGF1 INS
8 cellular MP:0005384 10.03 ADIPOQ DPP4 ENPP1 GCK IDE IGF1
9 cardiovascular system MP:0005385 9.93 ADIPOQ DPP4 ENPP1 GCK IDE IGF1
10 digestive/alimentary MP:0005381 9.92 GCG GHRL INS INSR LEP LEPR
11 immune system MP:0005387 9.73 ADIPOQ DPP4 ENPP1 IDE IGF1 INS
12 integument MP:0010771 9.28 ADIPOQ ENPP1 IDE IGF1 INS LEP

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 392)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
2
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
3
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Ethanol Approved Phase 4 64-17-5 702
7
Pitavastatin Approved Phase 4 147511-69-1 5282452
8
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
9
Losartan Approved Phase 4 114798-26-4 3961
10
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
11
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
14
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
15
Nitric Oxide Approved Phase 4 10102-43-9 145068
16
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
17
Hydroxychloroquine Approved Phase 4 118-42-3 3652
18
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
19
Dulaglutide Approved, Investigational Phase 4 923950-08-7
20
Mecobalamin Approved, Investigational Phase 4 13422-55-4
21
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
22
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
23
Methyltestosterone Approved Phase 4 58-18-4 6010
24
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
25
Testosterone enanthate Approved Phase 4 315-37-7 9416
26
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
27
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
28
Dapagliflozin Approved Phase 4 461432-26-8 9887712
29
Nutmeg Approved Phase 4
30
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
31
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
32
Atorvastatin Approved Phase 4 134523-00-5 60823
33
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
34
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
35
Candesartan cilexetil Approved Phase 4 145040-37-5
36
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
37
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
38
Saxagliptin Approved Phase 4 361442-04-8 11243969
39
Amlodipine Approved Phase 4 88150-42-9 2162
40
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
41
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
42
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
43
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
46
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
47
2,4-thiazolidinedione Investigational Phase 4 2295-31-0 5437
48
Cobalamin Experimental Phase 4 13408-78-1 6857388
49
Candesartan Experimental Phase 4 139481-59-7 2541
50 Analgesics Phase 4

Interventional clinical trials:

(show top 50) (show all 656)
# Name Status NCT ID Phase Drugs
1 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
2 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
3 Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes Unknown status NCT03917784 Phase 4 Curcumin;Starch
4 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
5 Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome Unknown status NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
6 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
7 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
8 The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08 Completed NCT00740363 Phase 4 sitagliptin;placebo
9 Effect of Dexmedetomidine on Postoperative Glucose Levels and Insulin Secretion Patterns in Obese Patients With Impaired Glucose Tolerance. Completed NCT03809182 Phase 4 Dexmedetomidine;0.9% Sodium-chloride;Fentanyl;Morphine Sulfate
10 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
11 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
12 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS Completed NCT01497132 Phase 4 Vitamin D3;Placebo
13 A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
14 Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment Completed NCT03006471 Phase 4 Dapagliflozin;Placebo - Cap
15 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
16 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
17 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
18 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
19 Effect of Linagliptin + Metformin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients With Prediabetes Who do Not Achieve Normoglycemia After 12 Months of Treatment With Metformin Alone Completed NCT04088461 Phase 4 Linagliptin / Metformin Oral Tablet;Metformin
20 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
21 Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes Completed NCT02744976 Phase 4 Metformin
22 The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus Completed NCT00456885 Phase 4 exenatide;Placebo
23 Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol with concomitant losartan or lisinopril;HCTZ with concomitant losartan or lisinopril;Placebo with concomitant losartan or lisinopril
24 Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
25 The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance Completed NCT00546728 Phase 4 Exenatide;Metformin
26 Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
27 Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
28 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone
29 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
30 Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
31 Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance Completed NCT00319189 Phase 4 Nateglinide
32 A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt) Completed NCT00241072 Phase 4 valsartan
33 Diet and Exercise in Type 2 Diabetes and Prediabetes Completed NCT00928005 Phase 4
34 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
35 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4 Exenatide
36 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
37 Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons? Completed NCT01219231 Phase 4
38 The Effect of Metformin on Clinical Course of Ischemic Etiology Chronic Heart Failure in Patients With Prediabetes: the Open-label Randomized Clinical Trial Completed NCT04549415 Phase 4 Metformin Hydrochloride
39 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
40 Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
41 Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial Completed NCT01765946 Phase 4 Metformin;placebo
42 Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function Completed NCT01588418 Phase 4 Exenatide;Placebo
43 The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus Completed NCT01911663 Phase 4
44 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Recruiting NCT04387201 Phase 4 Cyanocobalamin;Dulaglutide
45 52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese/Overweight Men With T2DM/Prediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters Recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
46 The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study Recruiting NCT03938389 Phase 4 Sacubitril-Valsartan Tab 97-103 MG;Valsartan 160mg;Placebo Oral Tablet
47 Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes Recruiting NCT05119179 Phase 4 Semaglutide
48 Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial Recruiting NCT05426525 Phase 4 Empagliflozin;Multivitamin-Placebo
49 Effect of Administration of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Prediabetes Active, not recruiting NCT03029390 Phase 4 Metformin
50 The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction Not yet recruiting NCT05050500 Phase 4 Dapagliflozin 10mg/Tab;Placebo

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 71 / NDF-RT 50 :


glucomannan

Cochrane evidence based reviews: glucose intolerance

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 28

Anatomical Context for Glucose Intolerance

Organs/tissues related to Glucose Intolerance:

MalaCards : Pancreatic Islet, Skeletal Muscle, Ovary, Liver, Heart, Adipocyte, Endothelial

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 11339)
# Title Authors PMID Year
1
Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. 53 62
20332348 2010
2
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. 53 62
20469868 2010
3
Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. 53 62
19914667 2010
4
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. 53 62
20147524 2010
5
Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage? 53 62
19815054 2010
6
Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). 53 62
20105040 2010
7
Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. 53 62
19804472 2010
8
Retinol-binding protein 4 levels in obese children and adolescents with glucose intolerance. 53 62
20389103 2010
9
Adiponectin in insulin resistance: lessons from translational research. 53 62
19906806 2010
10
Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. 53 62
19697961 2009
11
Acromegaly pathogenesis and treatment. 53 62
19884662 2009
12
The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. 53 62
19688613 2009
13
The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. 53 62
19576817 2009
14
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. 53 62
19542241 2009
15
Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss. 53 62
19627193 2009
16
Pre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity. 53 62
18793347 2009
17
Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. 53 62
18624998 2009
18
Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. 53 62
19003725 2009
19
Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes. 53 62
19260948 2009
20
Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. 53 62
18847384 2009
21
A cross-sectional study for glucose intolerance of myotonic dystrophy. 53 62
18834994 2009
22
Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. 53 62
18812482 2008
23
[Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients]. 53 62
19140314 2008
24
Ketogenic diet-fed rats have increased fat mass and phosphoenolpyruvate carboxykinase activity. 53 62
18655006 2008
25
Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. 53 62
18647805 2008
26
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. 53 62
18633104 2008
27
Associations between sex hormone binding globulin and metabolic syndrome parameters in premenopausal obese women. 53 62
19008614 2008
28
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. 53 62
18854155 2008
29
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. 53 62
18803955 2008
30
High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. 53 62
18492757 2008
31
A cross-sectional study of the association between persistent organic pollutants and glucose intolerance among Greenland Inuit. 53 62
18560802 2008
32
Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. 53 62
18334585 2008
33
Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. 53 62
18388893 2008
34
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. 53 62
17706206 2008
35
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. 53 62
17904401 2008
36
Adiponectin and its role in cardiovascular diseases. 53 62
18336252 2008
37
Insulin and its role in chronic kidney disease. 53 62
17929061 2008
38
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. 53 62
17944883 2008
39
Suppressive effects of diacylglycerol oil on postprandial hyperlipidemia in insulin resistance and glucose intolerance. 53 62
17125771 2007
40
How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. 53 62
17387006 2007
41
Glucocorticoids and cardiovascular disease. 53 62
17984234 2007
42
Muscle GLUT4 in cirrhosis. 53 62
17448565 2007
43
Fetal determinants of type 2 diabetes. 53 62
17691930 2007
44
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. 53 62
16814296 2007
45
Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance. 53 62
17512320 2007
46
Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. 53 62
17418606 2007
47
[Effect of progressive insulin resistance on the correlation of glucose metabolism and bone status]. 53 62
17561482 2007
48
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. 53 62
17403409 2007
49
Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. 53 62
17503657 2007
50
'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. 53 62
17389771 2007

Variations for Glucose Intolerance

ClinVar genetic disease variations for Glucose Intolerance:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MT-TL1 NC_012920.1:m.3243A>G SNV Pathogenic
9589 rs199474657 GRCh37: MT:3243-3243
GRCh38: MT:3243-3243

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Pathways for Glucose Intolerance



Pathways directly related to Glucose Intolerance:

# Pathway Source
1 Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM) Reactome 66

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1 13.67 LEPR LEP INSR INS IGF1 IDE
2
Show member pathways
12.83 SLC2A4 PCK2 INSR INS IGF1
3
Show member pathways
12.77 SLC2A4 RETN LEP INSR INS ADIPOQ
4
Show member pathways
12.43 SLC2A4 LPL LEP ADIPOQ
5
Show member pathways
12.4 SLC2A4 LPL INSR ENPP1
6 12.4 SLC2A4 PCK2 INSR INS GCG ENPP1
7
Show member pathways
12.14 LEP INS IGF1 GHRL GCG DPP4
8
Show member pathways
12.1 SLC2A4 LEP INSR INS
9
Show member pathways
11.96 ADIPOQ INS INSR LEP LEPR SLC2A4
10
Show member pathways
11.73 PCK2 LPL ADIPOQ
11 11.61 SLC2A4 LPL LEP INS IGF1 ADIPOQ
12
Show member pathways
11.54 DPP4 GCG LEP
13 11.48 SLC2A4 LEPR LEP
14 11.44 LEPR LEP INSR INS
15
Show member pathways
11.38 LPL INS GCK
16 11.34 SLC2A4 RETN PCK2 LPL LEP INS
17 11.32 LEPR LEP INSR INS ADIPOQ
18
Show member pathways
11.2 LEPR LEP INSR INS
19 11.17 INSR INS GCK
20 11.05 SLC2A4 INSR ADIPOQ
21 11.04 SLC2A4 INSR INS
22 11.01 LEPR LEP INS GHRL
23 10.97 INS INSR SLC2A4
24 10.9 SLC2A4 INS GPT
25
Show member pathways
10.86 SLC2A4 INSR
26 10.7 SLC2A4 PCK2 LEP INSR ADIPOQ
27 10.37 SLC2A4 GCG

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.98 RETN LPL LEP INS IGF1 IDE
2 extracellular region GO:0005576 9.7 ADIPOQ DPP4 ENPP1 GCG GHRL IDE

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 10.18 LEP INSR INS IGF1
2 positive regulation of MAPK cascade GO:0043410 10.15 ADRB3 GHRL IGF1 INS INSR LEP
3 positive regulation of cold-induced thermogenesis GO:0120162 10.13 LEPR LEP GHRL ADRB3 ADIPOQ
4 carbohydrate metabolic process GO:0005975 10.11 SLC2A4 INSR INS GCK ADRB3
5 generation of precursor metabolites and energy GO:0006091 10.1 ADIPOQ ADRB3 ENPP1
6 positive regulation of insulin secretion GO:0032024 10.1 GCK GHRL PCK2
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.1 IGF1 INS INSR LEP
8 regulation of insulin secretion GO:0050796 10.09 GCG GCK LEP
9 response to activity GO:0014823 10.09 LEP GCG ADIPOQ
10 gluconeogenesis GO:0006094 10.08 PCK2 LEPR GCG
11 brown fat cell differentiation GO:0050873 10.02 ADIPOQ ADRB3 SLC2A4
12 glucose metabolic process GO:0006006 10.02 LEP INS GHRL GCK ADIPOQ
13 positive regulation of mitotic nuclear division GO:0045840 10.01 INSR INS IGF1
14 positive regulation of glucose import GO:0046326 10.01 INSR INS IGF1 ADIPOQ
15 activation of protein kinase B activity GO:0032148 10 INSR INS IGF1
16 positive regulation of glycolytic process GO:0045821 9.95 INSR INS IGF1
17 cellular response to leptin stimulus GO:0044320 9.94 GCK LEP
18 positive regulation of respiratory burst GO:0060267 9.93 INSR INS
19 energy reserve metabolic process GO:0006112 9.93 ADRB3 LEP LEPR
20 bone mineralization involved in bone maturation GO:0035630 9.9 LEP IGF1
21 regulation of bone remodeling GO:0046850 9.89 LEPR LEP
22 bone growth GO:0098868 9.88 LEPR LEP
23 negative regulation of feeding behavior GO:2000252 9.87 RETN INS
24 positive regulation of developmental growth GO:0048639 9.86 INSR LEP
25 negative regulation of gluconeogenesis GO:0045721 9.86 ADIPOQ GCK INS LEPR
26 glucose homeostasis GO:0042593 9.86 ADIPOQ GCG GCK INS INSR LEP
27 response to nutrient levels GO:0031667 9.82 LEP GHRL ADIPOQ
28 positive regulation of glycogen biosynthetic process GO:0045725 9.76 INSR INS IGF1 GCK
29 cellular response to insulin stimulus GO:0032869 9.53 SLC2A4 PCK2 LEP INSR GPT GCK

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.63 INS IGF1 ENPP1
2 insulin binding GO:0043559 9.56 INSR IDE
3 hormone activity GO:0005179 9.44 RETN LEP INS IGF1 GHRL GCG
4 insulin-like growth factor receptor binding GO:0005159 9.43 INSR INS IGF1

Sources for Glucose Intolerance

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....